Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene OK'd to Start US Trial of PD-1 Cancer Drug

publication date: Jan 13, 2016
BeiGene, a Beijing novel cancer drug company, will start a US Phase Ia/b clinical trial of BGB-A317, the company's humanized mAb that targets the immune checkpoint receptor PD-1. BeiGene expects to develop the molecule as a monotherapy and in combination with other cancer drugs to treat solid-organ and blood-borne cancers. The US tests will be part of a global trial; Australian tests are already underway, with 51 patients dosed by the end of November 2015. The trials are enrolling patients with relapsed or refractory solid tumors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here